CORT Stock Rises 42% in a Month: Here's What You Should Know

Corcept Therapeutics delivered multiple positive catalysts: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and the company plans to resubmit the NDA for relacorilant in Cushing’s syndrome with an FDA decision expected about six months later. Korlym sales reached $164.9 million, up about 5% year over year, and management raised 2026 revenue guidance to $950 million-$1.05 billion from $900 million-$1.0 billion. The stock has already rallied 41.8% in the past month and 113.3% year to date.

Analysis

The key market implication is not just that CORT has another regulatory catalyst; it is that the company is now transitioning from a binary single-asset story to a two-cash-flow platform, which should compress perceived duration risk and support a higher multiple. A successful relacorilant refile in Cushing’s would matter more than the label itself because it de-risks the FDA relationship after the CRL and validates the broader cortisol-platform thesis, making the ovarian cancer approval look less like a one-off and more like a repeatable development engine.

The second-order effect is competitive: once a selective glucocorticoid receptor antagonist is commercialized in two distinct indications, the market will start discounting Corcept as a specialty endocrine/oncology hybrid rather than a narrow rare-disease company. That widens the addressable investor base, but it also raises the bar on execution—launch uptake, payer access, and manufacturing reliability will matter more than headline approvals. The most important near-term variable is not the six-month PDUFA clock; it is whether management can convert regulatory momentum into a clean revenue inflection before investors re-rate the story back to “approval without sales.”

The move looks directionally justified but partially crowded after a 40% monthly run and >100% YTD gain. Consensus appears to be underweighting how much of the upside is already in the stock if the Cushing’s resubmission is merely accepted, versus approved on the first pass; the asymmetry now shifts toward execution disappointment or a slower-than-expected launch curve. The contrarian risk is that the market is extrapolating a platform multiple before there is proof that Lifyorli can offset Korlym concentration quickly enough to sustain the new guidance range.

Key Decisions for Investors

• Maintain a tactical long CORT only into the NDA resubmission window, but hedge with short-dated calls or a partial trim after the event; the near-term upside is real, yet much of the approval optionality is already reflected after the sharp run.
• For unhedged longs, prefer a defined-risk bull call spread in CORT with 3-6 month expiry rather than outright stock; this captures the six-month PDUFA runway while limiting downside if the FDA asks for additional data or timing slips.
• Use any post-resubmission strength to rotate from CORT into a pair trade: long CORT / short a lower-quality single-product biotech with upcoming regulatory risk, targeting relative outperformance if Corcept’s platform narrative keeps expanding.
• If Lifyorli launch commentary in the next quarter shows meaningful prescription build, add on weakness; the highest-multiple rerating catalyst will be evidence that the second product can scale faster than Korlym decelerates.
• Avoid chasing INDV/LQDA/IMCR as collateral biotech beta plays from this headline; their move is more sentiment-driven than fundamental, so the cleaner expression is CORT-specific event risk rather than basket exposure.